程序性死亡因子-1及其配体-1在子宫腺肌病中的表达及意义

doi:10.6040/j.issn.1671-7554.0.2017.157

摘要/Abstract

摘要： 目的探讨子宫腺肌病中程序性死亡因子-1(PD-1)及其配体-1(PD-L1)的表达,以及PD-1/PD-L1信号通路在子宫腺肌病发生发展中的作用。方法采用免疫组织化学法及Western blotting检测不同月经周期的子宫腺肌病在位内膜与异位子宫内膜、正常子宫内膜组织标本中PD-1、PD-L1蛋白的表达(每组增生期:n=15、分泌期:n=15)。分析不同组别间PD-1、PD-L1蛋白的表达差异及其与月经周期的关系。结果免疫组织化学结果显示,PD-1、PD-L1在不同月经周期的正常子宫内膜及腺肌病在位、异位子宫内膜中均有表达。腺肌病异位子宫内膜中PD-1蛋白(P<0.01)与PD-L1蛋白(P<0.01)表达升高。Western blotting结果显示,腺肌病在位子宫内膜中PD-1蛋白(P<0.01)与PD-L1蛋白(P<0.01)的表达增高。但在腺肌病组内不同月经周期中,PD-1/PD-L1的表达水平差异无统计学意义(P=0.12; P=0.45)。结论 PD-1蛋白及PD-L1蛋白在腺肌病在位及异位子宫内膜中的表达升高,提示PD-1/PD-L1信号通路可能参与子宫腺肌病的发生、发展过程。

关键词: 子宫腺肌病, 程序性死亡因子-1, 免疫耐受, 程序性死亡因子配体-1, 子宫内膜

Abstract: Objective To investigate the expression and significance of PD-1 and its ligand PD-L1 in adenomyosis. Methods The expression level of PD-1 and PD-L1 in normal endometria, eutopic and ectopic adenomyotic endometria were determined by immunohistochemistry and Western blotting(proliferative phase n=15; secretory phase n=15 in each group). In addition, the relationship between different expressions of PD-1/PD-L1 among groups and menstrual cycle was analyzed. Results PD-1/PD-L1 expressed in both normal and adenomyotic endometria of different menstrual cycles. In addition, expressions of PD-1/PD-L1 in both ectopic and eutopic adenomyotic endometria were upregulated(P<0.01). However, there was no difference between proliferative phase and secretory phase in PD-1/PD-L1 expression of eutopic adenomyotic endometria(P=0.12; P=0.45). Conclusion The expressions of PD-1 and PD-L1 are upregulated in adenomyotic endometria, suggesting that the PD-1/PD-L1 pathway may be involved in the immune dysfunctions and pathogenesis of adenomyosis.

Key words: Adenomyosis, Programmed cell death-ligand 1, Immunotolerance, Programmed death-1, Endometrium

中图分类号:

R711.71

吴卢侃璇,朱珊,于金习,吕椿子,李明江. 程序性死亡因子-1及其配体-1在子宫腺肌病中的表达及意义[J]. 山东大学学报（医学版）, 2017, 55(10): 90-96.

WU Lukanxuan, ZHU Shan, YU Jinxi, LÜ Chunzi, LI Mingjiang. Expression and significance of programmed death-1 and its ligand PD-L1 in adenomyosis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 90-96.

参考文献

[1] 郎景和. 关于子宫内膜异位症的再认识及其意义[J]. 中国工程科学, 2009:137-142.
[2] Tremellen KP, Russell P. The distribution of immune cells and macrophages in the endometrium of women with recurrent reproductive failure. Ii: Adenomyosis and macrophages[J]. J Reprod Immunol, 2012, 93(1): 58-63.
[3] Wang F, Wen Z, Li H, et al. Human leukocyte antigen-g is expressed by the eutopic and ectopic endometrium of adenomyosis[J]. Fertil Steril, 2008, 90(5): 1599-1604.
[4] Yu JJ, Sun HT, Zhang ZF, et al. Il15 promotes growth and invasion of endometrial stromal cells and inhibits killing activity of nk cells in endometriosis[J]. Reproduction, 2016, 152(2): 151-160.
[5] O DF, Roskams T, Van den Eynde K, et al. The presence of endometrial cells in peritoneal fluid of women with and without endometriosis[J]. Reprod Sci, 2017, 24(2): 242-251.
[6] Okazaki T, Honjo T. The pd-1-pd-l pathway in immunological tolerance[J]. Trends Immunol, 2006, 27(4): 195-201.
[7] Francisco LM, Sage PT, Sharpe AH. The pd-1 pathway in tolerance and autoimmunity[J]. Immunol Rev, 2010, 236: 219-242. doi: 10.1111/j.1600-065X.2010.00923.x.
[8] Chikuma S. Basics of pd-1 in self-tolerance, infection, and cancer immunity[J]. Int J Clin Oncol, 2016, 21(3): 448-455.
[9] Sotnikova N, Antsiferova I, Malyshkina A. Cytokine network of eutopic and ectopic endometrium in women with adenomyosis[J]. Am J Reprod Immunol, 2002, 47(4): 251-255.
[10] 张爱荣, 吴继海, 胡本忠, 等. 子宫内膜异位症并不孕患者腹腔液及外周血中细胞因子的变化[J]. 山东大学学报(医学版), 2004, 42(4): 460-462. ZHANG Airong, WU Jihai, HU Benzhong, et al. Interleukin variation in peritoneal fluid and serum of patients with endometriosis-related infertility[J]. Journal of Shandong University(Health Sciences), 2004, 42(4): 460-462.
[11] 王立杰, 冷金花, 郎景和. IL-8在子宫内膜异位症发病中的作用[J]. 山东大学学报(医学版), 2004, 42(4): 456-459. WANG Lijie, LENG Jinhua, LANG Jinghe. Role of interleukine-8 in the pathogenesis of endometriosis[J]. Journal of Shandong University(Health Sciences), 2004, 42(4): 456-459.
[12] Nishimura H, Honjo T. Pd-1: An inhibitory immunoreceptor involved in peripheral tolerance[J]. Trends Immunol, 2001, 22(5): 265-268.
[13] Keir ME, Butte MJ, Freeman GJ, et al. Pd-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
[14] Latchman Y, Wood CR, Chernova T, et al. Pd-l2 is a second ligand for pd-1 and inhibits t cell activation[J]. Nat Immunol, 2001, 2(3): 261-268.
[15] Scheerer C, Bauer P, Chiantera V, et al. Characterization of endometriosis-associated immune cell infiltrates(emaici)[J]. Arch Gynecol Obstet, 2016, 294(3): 657-664.
[16] Dong H, Strome SE, Salomao DR, et al. Tumor-associated b7-h1 promotes t-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800.
[17] Mazanet MM, Hughes CC. B7-h1 is expressed by human endothelial cells and suppresses t cell cytokine synthesis[J]. J Immunol, 2002, 169(7): 3581-3588.
[18] Kim S, Koh J, Kim MY, et al. Pd-l1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung[J]. Hum Pathol, 2016, 58: 7-14. doi:10.1016/j.humpath.2016.07.007.
[19] Webb JR, Milne K, Kroeger DR, et al. Pd-l1 expression is associated with tumor-infiltrating t cells and favorable prognosis in high-grade serous ovarian cancer[J]. Gynecol Oncol, 2016, 141(2): 293-302.
[20] Madore J, Strbenac D, Vilain R, et al. Pd-l1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-iii melanoma[J]. Clin Cancer Res, 2016, 22(15): 3915-3923.
[21] Madore J, Vilain RE, Menzies AM, et al. Pd-l1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-pd-1/pd-l1 clinical trials[J]. Pigment Cell Melanoma Res, 2015, 28(3): 245-253.
[22] Merelli B, Massi D, Cattaneo L, et al. Targeting the pd1/pd-l1 axis in melanoma: biological rationale, clinical challenges and opportunities[J]. Crit Rev Oncol Hematol, 2014, 89(1): 140-165.
[23] Chang K, Svabek C, Vazquez-Guillamet C, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses t cell exhaustion in patients with sepsis[J]. Crit Care, 2014, 18(1): R3. doi: 10.1186/cc13176.
[24] Yang L, Huang F, Mei J, et al. Posttranscriptional control of pd-l1 expression by 17beta-estradiol via pi3k/akt signaling pathway in eralpha-positive cancer cell lines[J]. Int J Gynecol Cancer, 2017, 27(2): 196-205.

相关文章 15

[1]	张舒淇,江延姣,印丹. 生殖道微生物与子宫内膜异位症发展之间的联系[J]. 山东大学学报 (医学版), 2025, 63(5): 120-126.
[2]	徐萍,张信美. 子宫内膜异位症疼痛的机制[J]. 山东大学学报 (医学版), 2025, 63(10): 1-7.
[3]	黄艳,周应芳,彭超. 青少年子宫内膜异位症的管理要点和策略[J]. 山东大学学报 (医学版), 2025, 63(10): 8-12.
[4]	薛铭,梁静,凌斌. 各种类型子宫内膜异位症疼痛特点及治疗研究进展[J]. 山东大学学报 (医学版), 2025, 63(10): 13-19.
[5]	赵书睿,赵烨. 围绝经期及绝经后期子宫内膜异位症的诊疗现状[J]. 山东大学学报 (医学版), 2025, 63(10): 20-26.
[6]	梁炎春,严莹,麦华希,姚书忠. 地诺孕素在子宫内膜异位症相关性疼痛中的治疗作用:从基础到临床[J]. 山东大学学报 (医学版), 2025, 63(10): 27-33.
[7]	董向毅,刘昕,刘欣欣,徐亚瑄,赵琳丽,陶国伟. 盆腔深部子宫内膜异位症的超声评价[J]. 山东大学学报 (医学版), 2025, 63(10): 34-42.
[8]	刘振花,连雅囡,米国琳. 子宫内膜异位症疼痛的心理因素及干预措施的研究进展[J]. 山东大学学报 (医学版), 2025, 63(10): 43-51.
[9]	杜煜晗,孙莹,杜惠兰. 红花如意丸对寒凝血瘀型子宫内膜异位症痛经患者疼痛的疗效及机制[J]. 山东大学学报 (医学版), 2025, 63(10): 52-60.
[10]	张扬,刘帅,邓明铭,王秋敏,黄玉真,颜磊. 宫腔镜子宫内膜息肉切除至取卵的时间间隔对IVF/ICSI鲜胚移植妊娠结局的影响[J]. 山东大学学报 (医学版), 2025, 63(10): 80-88.
[11]	赵圣蕊,曲慧灵,许鑫鑫,张芳芳,颜磊. 体外受精/卵胞浆内单精子注射-胚胎移植后稽留流产采用药物流产和清宫术效果比较[J]. 山东大学学报 (医学版), 2024, 62(2): 69-74.
[12]	李军秀,袁莹莹,黄凌燕,赵君利. 子宫内膜CD38表达对胚胎移植前抗炎治疗的临床价值[J]. 山东大学学报 (医学版), 2023, 61(8): 54-60.
[13]	吴磊丽,蔡华丽,孙德胜,魏蔚霞. 超声引导穿刺硬化术联合地诺孕素治疗卵巢子宫内膜异位囊肿的疗效[J]. 山东大学学报 (医学版), 2023, 61(6): 65-69.
[14]	戚丹,张曦,于倩,崔琳琳,颜磊. 子宫内膜增生症及早期子宫内膜癌保留生育功能后冻胚移植妊娠结局[J]. 山东大学学报 (医学版), 2023, 61(4): 56-63.
[15]	常鑫,刘世佳,韩璐. 服用阿司匹林与子宫内膜癌发病风险的孟德尔随机化关系[J]. 山东大学学报 (医学版), 2023, 61(10): 58-62.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed